Scholar Rock Holding Corp

Research Scholar Rock Holding Corp (SRRK) on Bullrun: market cap USD 7.08B. Explore financials, valuation history, model signals, and stock context.

Key Metrics

Valuation Snapshot

latest market cap is USD 7.08B.

Five-year financial history

YearRevenueNet incomeFree cash flowGross marginDiluted EPSCashTotal debtEquity
FY2025USD 0-USD 378.00M-USD 300.64Mn/a-3.29USD 323.53MUSD 99.71MUSD 245.49M
FY2024USD 0-USD 246.00M-USD 201.05Mn/a-2.47USD 177.88MUSD 50.15MUSD 368.63M
FY2023n/a-USD 166.00M-USD 145.30Mn/a-1.99USD 101.86MUSD 50.02MUSD 225.22M
FY2022USD 33.19M-USD 134.50M-USD 133.76Mn/a-2.26USD 103.28MUSD 49.74MUSD 260.24M

Valuation history

YearSnapshot dateMarket capP/EDividend yieldAnnual dividend/share
20262026-08-25USD 7.08Bn/an/an/a
20252025-12-31USD 4.78Bn/an/an/a
20242024-12-31USD 4.06Bn/an/an/a
20232023-12-29USD 1.36Bn/an/an/a
20222022-12-30USD 467.55Mn/an/an/a
20212021-12-31USD 874.59Mn/an/an/a

About Scholar Rock Holding Corp

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on improving the lives of children and adults with spinal muscular atrophy (SMA) and other rare, severe, and debilitating neuromuscular diseases. The company's novel understanding of the molecular mechanisms of growth factor activation within the transforming growth factor beta (TGFß) superfamily has enabled the development of a proprietary platform.

Related stock research

Other Healthcare stocks

Frequently asked questions

What is Scholar Rock Holding Corp's market cap?

Scholar Rock Holding Corp's market capitalization is USD 7.08B.

What does Scholar Rock Holding Corp do?

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on improving the lives of children and adults with spinal muscular atrophy (SMA) and other rare, severe, and debilitating neuromuscular diseases. The company's novel understanding of the molecular mechanisms of growth factor activation within the transforming growth factor beta (TGFß) superfamily has enabled the development of a proprietary platform. This platform is used for the development of monoclonal antibodies that locally and selectively target the precursor, or latent, forms of growth factors.